Deals
Jacobio discovered JAB-23E73, which is designed to treat several KRAS mutation subtypes, and is testing the therapy in multiple Phase I trials.
FEATURED STORIES
2026 is set to be a banner year for M&A in biopharma, as buyers facing major patent cliffs fight for a small pool of late-stage assets.
Metsera showed the biopharma world that M&A is back. Who could be next?
These deals radically reshaped the biopharma world, either by one vaccine rival absorbing another, a Big Pharma doubling down after another failed acquisition or, in the case of Pfizer and Novo, two heavyweights duking it out over a hot obesity biotech.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Find out which biopharma companies are raking in the cash this week, as companies from around the globe provide updates on their financing rounds and IPOs.
The deal, which is worth up to $2.15 billion, is expected to close in the first quarter of 2021 and is subject to regulatory approval.
Bayer is paying $2 billion upfront for AskBio’s AAV-based gene therapy pipeline of treatments for Pompe disease, among others, and could pay an additional $2 billion in potential milestones.
Foghorn Therapeutics hits the Nasdaq offering 7.5 million shares at $16 apiece.
Bay Area-based insitro snapped up neighboring Haystack Sciences to bolster its machine-learning drug discovery programs with that company’s higher resolution dataset-producing technology.
OT-58 is Orphan’s novel investigational enzyme replacement therapy. It is currently in Phase I/II development for classical HCU, a rare metabolic disorder marked by increased levels of plasma homocysteine.
Arixa Pharmaceuticals announced on Thursday that Pfizer’s hospital business has agreed to acquire the company. Arixa has been developing oral antibiotics for antibiotic-resistant Gram-negative infections.
Find out which biopharma companies are raking in the cash this week, as companies from around the globe provide updates on their financing rounds and IPOs.
This morning, the company, which was formerly known as EpiPM Therapeutics, will begin trading on the Nasdaq Global Select Market under the ticker symbol PRAX.
Eli Lilly is betting on a new approach to axonal degeneration, announcing a definitive agreement to acquire Disarm Therapeutics, a privately-held biotech company committed to solving this mystery.